Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study

Boris Decourt; Aaron Walker; Amanda Gonzales; Michael Malek-Ahmadi; Carolyn Liesback; Kathryn J. Davis; Christine M. Belden; Sandra A. Jacobson; Marwan N. Sabbagh

doi:10.3109/09537104.2012.688899

Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study

Boris Decourt, Aaron Walker, Amanda Gonzales, Michael Malek-Ahmadi, Carolyn Liesback, Kathryn J. Davis, Christine M. Belden, Sandra A. Jacobson, Marwan N. Sabbagh

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

To date there is no validated peripheral biomarker to assist with the clinical diagnosis of Alzheimer's disease (AD). Platelet proteins have been studied as AD biomarkers with relative success. In this study, we investigated whether platelet BACE1 levels differ between AD and cognitively normal (CN) control patients. Using a newly developed ELISA method, we found that BACE1 levels were significantly lower in AD compared to CN subjects. These data were supported by the observation that several BACE1 isoforms, identified by Western blotting, were also lower in AD platelets. This proof-of-concept study provides evidence for testing platelet BACE1 levels as a peripheral AD biomarker using a novel, sensitive and inexpensive method.

Original language	English (US)
Pages (from-to)	235-238
Number of pages	4
Journal	Platelets
Volume	24
Issue number	3
DOIs	https://doi.org/10.3109/09537104.2012.688899
State	Published - 2013
Externally published	Yes

Keywords

Alzheimer's disease
BACE1
Biomarker
Peripheral
Platelets

ASJC Scopus subject areas

Hematology

Access to Document

10.3109/09537104.2012.688899

Cite this

@article{735f3c53003949db9ac28d9a536d584e,

title = "Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study",

abstract = "To date there is no validated peripheral biomarker to assist with the clinical diagnosis of Alzheimer's disease (AD). Platelet proteins have been studied as AD biomarkers with relative success. In this study, we investigated whether platelet BACE1 levels differ between AD and cognitively normal (CN) control patients. Using a newly developed ELISA method, we found that BACE1 levels were significantly lower in AD compared to CN subjects. These data were supported by the observation that several BACE1 isoforms, identified by Western blotting, were also lower in AD platelets. This proof-of-concept study provides evidence for testing platelet BACE1 levels as a peripheral AD biomarker using a novel, sensitive and inexpensive method.",

keywords = "Alzheimer's disease, BACE1, Biomarker, Peripheral, Platelets",

author = "Boris Decourt and Aaron Walker and Amanda Gonzales and Michael Malek-Ahmadi and Carolyn Liesback and Davis, {Kathryn J.} and Belden, {Christine M.} and Jacobson, {Sandra A.} and Sabbagh, {Marwan N.}",

note = "Funding Information: Declaration of Interest: This study was supported by National Institute on Aging grants R01AG034155 and P30AG019610-09. The authors declare no conflict of interest.",

year = "2013",

doi = "10.3109/09537104.2012.688899",

language = "English (US)",

volume = "24",

pages = "235--238",

journal = "Platelets",

issn = "0953-7104",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study

AU - Decourt, Boris

AU - Walker, Aaron

AU - Gonzales, Amanda

AU - Malek-Ahmadi, Michael

AU - Liesback, Carolyn

AU - Davis, Kathryn J.

AU - Belden, Christine M.

AU - Jacobson, Sandra A.

AU - Sabbagh, Marwan N.

N1 - Funding Information: Declaration of Interest: This study was supported by National Institute on Aging grants R01AG034155 and P30AG019610-09. The authors declare no conflict of interest.

PY - 2013

Y1 - 2013

N2 - To date there is no validated peripheral biomarker to assist with the clinical diagnosis of Alzheimer's disease (AD). Platelet proteins have been studied as AD biomarkers with relative success. In this study, we investigated whether platelet BACE1 levels differ between AD and cognitively normal (CN) control patients. Using a newly developed ELISA method, we found that BACE1 levels were significantly lower in AD compared to CN subjects. These data were supported by the observation that several BACE1 isoforms, identified by Western blotting, were also lower in AD platelets. This proof-of-concept study provides evidence for testing platelet BACE1 levels as a peripheral AD biomarker using a novel, sensitive and inexpensive method.

AB - To date there is no validated peripheral biomarker to assist with the clinical diagnosis of Alzheimer's disease (AD). Platelet proteins have been studied as AD biomarkers with relative success. In this study, we investigated whether platelet BACE1 levels differ between AD and cognitively normal (CN) control patients. Using a newly developed ELISA method, we found that BACE1 levels were significantly lower in AD compared to CN subjects. These data were supported by the observation that several BACE1 isoforms, identified by Western blotting, were also lower in AD platelets. This proof-of-concept study provides evidence for testing platelet BACE1 levels as a peripheral AD biomarker using a novel, sensitive and inexpensive method.

KW - Alzheimer's disease

KW - BACE1

KW - Biomarker

KW - Peripheral

KW - Platelets

UR - http://www.scopus.com/inward/record.url?scp=84875745149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875745149&partnerID=8YFLogxK

U2 - 10.3109/09537104.2012.688899

DO - 10.3109/09537104.2012.688899

M3 - Article

C2 - 22775589

AN - SCOPUS:84875745149

SN - 0953-7104

VL - 24

SP - 235

EP - 238

JO - Platelets

JF - Platelets

IS - 3

ER -

Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this